|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Dr. Day is a prominent researcher examining, among other studies, nitric oxide to treat children suffering from pulmonary hypertension. Dr. Day recently spoke with The Life Science Report where he discussed the benefits of investigating nitric oxide treatments. Nu-Med Plus recently developed the Nu-Med Plus 100 (NMP 100), the world’s first nitric oxide dilution system purpose-built for research.
A Federal Circuit Court ruling in May invalidated the majority of a patent for a dominant nitric oxide producer, which allowed a single company to sell nitric oxide gas for medical use. Now other gas supply companies are expected to enter and expand the medical nitric oxide market. With the monopoly broken the resulting market expansion will result in a greater demand for Nu-Med Plus delivery devices explains Jeff Robins, CEO of Nu-Med Plus.
The announcement comes in anticipation of near-term FDA 510(k) fillings for Nu-Med Plus nitric oxide delivery devices. ISO 13485 is an international standard that specifies requirements for a quality management system for design, development and manufacture of medical devices.
The firm produces compelling public relations campaigns and social media strategies that will help drive awareness of Nu-Med Plus and its innovative approach to nitric oxide delivery. The team of former journalists, startup executives, and public relations practitioners will further help guide the expansion of Nu-Med Plus, Inc. and its Inhaled Nitric Oxide(INO) products throughout the financial arena.